In May 2008 Bell Pottinger USA worked with The National Organization for Rare Disorders (NORD) to announce that its board has unanimously selected Peter Saltonstall to be the organization’s new President and Chief Executive officer.
The appointment comes as NORD celebrates its 25th anniversary and the 25th anniversary of the landmark Orphan Drug Act which provides incentives for development of therapies for people with “orphan” diseases affecting 200,000 or fewer people in this country.
END
About Bell Pottinger USA:
Bell Pottinger USA (BPUSA), part of the number 1 PR Group, Bell Pottinger, in the UK, is a strategic public relations firm based in Boston, Massachusetts with offices in New York City and Washington, D.C. BPUSA is a full-service, multi-disciplinary public relations, government affairs and marketing services agency and serves all sectors, including technology, healthcare, education, non-profit, consumer, travel and tourism. For more information, please visit www.bellpottingerusa.com or call Managing Director, Marlin Collingwood, on +1 617 210 4755.
